BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has successfully ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced ...

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks ...

Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and ...

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers ...

Quanterix QTRX recently announced the submission of a 510(k) premarket notification to the FDA for its multi-analyte algorithmic blood test designed to aid in the evaluation of patients with cognitive ...

Quanterix Corporation, announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer’s disease (AD) ...

Quanterix Corporation (NASDAQ:QTRX) Q4 2024 Earnings Call Transcript March 17, 2025 Quanterix Corporation misses on earnings expectations. Reported EPS is $-0.3 EPS, expectations were $-0.27. Operator ...

Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling ...